1887

Chapter 7 : Inhibitors of the Human Immunodeficiency Virus Protease

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Inhibitors of the Human Immunodeficiency Virus Protease, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815493/9781555814397_Chap07-1.gif /docserver/preview/fulltext/10.1128/9781555815493/9781555814397_Chap07-2.gif

Abstract:

HIV protease inhibitors (PIs) were first introduced into clinical practice in 1996, and their use has resulted in major clinical benefits for human immunodeficiency virus (HIV) -infected people in terms of better viral suppression, improved immune restoration, reduced morbidity, and longer survival. This chapter focuses on the biochemical and molecular basis of inhibition of HIV-1 aspartic protease (PR), the virological basis of PI resistance, and implications on the therapeutics of HIV infections and proposes the research that is still needed in order to further improve on the benefits that PIs offer for HIV medicine. Drug-resistant viruses have been described for all PIs developed to date. Some strains of HIV recovered from extensively treated patients display cross-resistance to a variety of PIs. Additionally, structural data from a highly resistant PR containing 10 resistance mutations revealed an expansion in the active site, as a result of a separation of the flaps by as much as 10 Å, while this distance is only 4 Å in the case of wild-type PR. The degree of suppression of viral replication is the result of the interaction between exposure of the virus to the drug and the inherent susceptibility of the infecting virus to such drug, all this within the diverse environments of human tissues. The study of efflux transporters and their role in PI penetration into, and distribution within, so-called sanctuary sites may lead to ways of making HIV in these compartments more susceptible to antiretrovirals (ARVs).

Citation: Martinez-Cajas J, Wainberg M. 2009. Inhibitors of the Human Immunodeficiency Virus Protease, p 113-135. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch7

Key Concept Ranking

Human immunodeficiency virus 1
0.4582152
Non-Nucleoside Reverse Transcriptase Inhibitors
0.40592992
0.4582152
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1.
Figure 1.

HIV protease inhibitors arrest maturation of the virus particle by blocking the processing of Gag and Gag-Pol. This prevents reorganization of the structural proteins within the virion. Any resultant virus particles are not infectious.

Citation: Martinez-Cajas J, Wainberg M. 2009. Inhibitors of the Human Immunodeficiency Virus Protease, p 113-135. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch7
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2.
Figure 2.

Schematic representation of nine cleavage sites within Gag and Gag-Pol. The PR enzyme recognizes heptamers within its natural substrates. S refers to a pocket in the protease that accepts a group P from the substrate. This nomenclature (by Schechter and Berger) is used for both natural substrates and inhibitors ( ).

Citation: Martinez-Cajas J, Wainberg M. 2009. Inhibitors of the Human Immunodeficiency Virus Protease, p 113-135. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch7
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3.
Figure 3.

The crystal structure of the wild-type HIV-1 PR. The flaps are flexible structures that open to permit entrance of the large Gag-Pol polyproteins. The aspartate residues in the active site confer hydrolytic activity to the enzyme. This figure was generated from the 3HVP structure in the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) using software available from PyMol DeLano Scientific, Palo Alto, CA.

Citation: Martinez-Cajas J, Wainberg M. 2009. Inhibitors of the Human Immunodeficiency Virus Protease, p 113-135. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch7
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 4.
Figure 4.

Transmission electron micrographs of HIVBal-infected monocytes/macrophages incubated with or without PIs at 20 μM for 5 days. (A) Control cells. Bullet-shaped “mature” cores of virus particles in an intracytoplasmic vacuole are visible. (B) Cells incubated with pepstatin A. The virions in this cell have mature cores. (C) Cells incubated with the PI SK&F 107461; , 48 nM. Many virions are “immature”; that is, they have Gag protein plaques and no cores. Some virions have mature cores. (D) Cells incubated with the PI SK&F 108922; , <10 nM. Almost all virions have immature morphology. Reprinted from the ( ) with permission of the publisher.

Citation: Martinez-Cajas J, Wainberg M. 2009. Inhibitors of the Human Immunodeficiency Virus Protease, p 113-135. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch7
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 5.
Figure 5.

Secondary structures of approved HIV-1 PIs.

Citation: Martinez-Cajas J, Wainberg M. 2009. Inhibitors of the Human Immunodeficiency Virus Protease, p 113-135. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch7
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 6.
Figure 6.

Common PI resistance mutations. Black box, major mutation; white box, minor mutation; gray arrow, wild-type consensus sequence. (Based on the IAS-USA list of HIV drug resistance mutations [66].)

Citation: Martinez-Cajas J, Wainberg M. 2009. Inhibitors of the Human Immunodeficiency Virus Protease, p 113-135. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch7
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815493.ch07
1. Abecasis, A. B.,, K. Deforche,, L. T. Bacheler,, P. McKenna,, A. P. Carvalho,, P. Gomes,, A. M. Vandamme, and, R. J. Camacho. 2006. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir. Ther. 11:581589.
2. Abecasis, A. B.,, K. Deforche,, J. Snoeck,, L. T. Bacheler,, P. McKenna,, A. P. Carvalho,, P. Gomes,, R. J. Camacho, and, A. M. Vandamme. 2005. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 19:17991806.
3. Acosta, E. P. 2002. Pharmacokinetic enhancement of protease inhibitors. J. Acquir. Immune Defic. Syndr. 29 (Suppl. 1):S11S18.
4. Acosta, E. P.,, A. Bardeguez,, C. D. Zorrilla,, R. Van Dyke,, M. D. Hughes,, S. Huang,, L. Pompeo,, A. M. Stek,, J. Pitt,, D. H. Watts,, E. Smith,, E. Jimenez, and, L. Mofenson. 2004. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob. Agents Chemother. 48:430436.
5. Ammassari, A.,, R. Murri,, P. Pezzotti,, M. P. Trotta,, L. Ravasio,, P. De Longis,, S. Lo Caputo,, P. Narciso,, S. Pauluzzi,, G. Carosi,, S. Nappa,, P. Piano,, C. M. Izzo,, M. Lichtner,, G. Rezza,, A. Monforte,, G. Ippolito,, M. d’Arminio Moroni,, A. W. Wu, and, A. Antinori. 2001. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J. Acquir. Immune Defic. Syndr. 28:445449.
6. Ananworanich, J.,, A. Hill,, U. Siangphoe,, K. Ruxrungtham,, W. Prasithsirikul,, P. Chetchotisakd,, S. Kiertiburanakul,, W. Munsakul,, P. Raksakulkarn,, S. Tansuphasawadikul,, R. Nuesch,, D. A. Cooper, and, B. Hirschel. 2005. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Antivir. Ther. 10:761767.
7. Ananworanich, J.,, B. Hirschel,, S. Sirivichayakul,, S. Ubolyam,, T. Jupimai,, W. Prasithsirikul,, P. Chetchotisakd,, S. Kiertiburanakul,, W. Munsakul,, P. Raksakulkarn,, S. Tansuphasawadikul,, M. Schutz,, W. Snowden, and, K. Ruxrungtham. 2006. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir. Antivir. Ther. 11:631635.
8. Ariyoshi, K.,, M. Matsuda,, H. Miura,, S. Tateishi,, K. Yamada, and, W. Sugiura. 2003. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J. Acquir. Immune Defic. Syndr. 33:336342.
9. Bachmeier, C. J.,, T. J. Spitzenberger,, W. F. Elmquist, and, D. W. Miller. 2005. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm. Res. 22:12591268.
10. Baldwin, J.,, M. Boron,, Y. Wang,, D. Schneck, and, N. Hopkins. 1998. Effects of food and antacid on bioavailability of the protease inhibitor PNU-140690 in healthy volunteers, abstr. 649. Abstr. 5th Conf. Retrovir. Opportun. Infect., Chicago, IL.
11. Bangsberg, D. R.,, E. P. Acosta,, R. Gupta,, D. Guzman,, E. D. Riley,, P. R. Harrigan,, N. Parkin, and, S. G. Deeks. 2006. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 20:223231.
12. Bangsberg, D. R.,, E. D. Charlebois,, R. M. Grant,, M. Holodniy,, S. G. Deeks,, S. Perry,, K. N. Conroy,, R. Clark,, D. Guzman,, A. Zolopa, and, A. Moss. 2003. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17:19251932.
13. Bangsberg, D. R.,, A. R. Moss, and, S. G. Deeks. 2004. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J. Antimicrob. Chemother. 53:696699.
14. Bangsberg, D. R.,, T. C. Porco,, C. Kagay,, E. D. Charlebois,, S. G. Deeks,, D. Guzman,, R. Clark, and, A. Moss. 2004. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J. Infect. Dis. 190:162165.
15. Barbour, J. D.,, F. M. Hecht,, T. Wrin,, T. J. Liegler,, C. A. Ramstead,, M. P. Busch,, M. R. Segal,, C. J. Petropoulos, and, R. M. Grant. 2004. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 18:16831689.
16. Bold, G.,, A. Fassler,, H. G. Capraro,, R. Cozens,, T. Klimkait,, J. Lazdins,, J. Mestan,, B. Poncioni,, J. Rosel,, D. Stover,, M. Tintelnot-Blomley,, F. Acemoglu,, W. Beck,, E. Boss,, M. Eschbach,, T. Hurli-mann,, E. Masso,, S. Roussel,, K. Ucci-Stoll,, D. Wyss, and, M. Lang. 1998. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J. Med. Chem. 41:33873401.
17. Brenner, B.,, J. P. Routy,, Y. Quan,, D. Moisi,, M. Oliveira,, D. Turner, and, M. A. Wainberg. 2004. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 18:16531660.
18. Brumme, Z. L.,, W. W. Dong,, K. J. Chan,, R. S. Hogg,, J. S. Montaner,, M. V. O’Shaughnessy, and, P. R. Harrigan. 2003. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 17:201208.
19. Bugelski, P. J.,, R. Kirsh, and, T. K. Hart. 1994. HIV protease inhibitors: effects on viral maturation and physiologic function in macrophages. J. Leukoc. Biol. 56:374380.
20. Calza, L.,, R. Manfredi, and, F. Chiodo. 2004. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J. Antimicrob. Chemother. 53:1014.
21. Carrillo, A.,, K. D. Stewart,, H. L. Sham,, D. W. Norbeck,, W. E. Kohlbrenner,, J. M. Leonard,, D. J. Kempf, and, A. Molla. 1998. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J. Virol. 72:75327541.
22. Castagna, A.,, N. Gianotti,, L. Galli,, A. Danise,, H. Hasson,, E. Boeri,, R. Hoetelmans,, D. Nauwelaers, and, A. Lazzarin. 2004. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen. Antivir. Ther. 9:537543.
23. Charpentier, C.,, D. Lecossier,, F. Clavel, and, A. Hance. 2003. Role of resistance and fitness in driving the evolution of the protease in patients failing treatment with protease inhibitors, abstr. 601. Abstr. 10th Conf. Retrovir. Opportun. Infect., Boston, MA, 10 to 14 February 2003.
24. Choo, E. F.,, B. Leake,, C. Wandel,, H. Imamura,, A. J. Wood,, G. R. Wilkinson, and, R. B. Kim. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 28:655660.
25. Clemente, J. C.,, R. M. Coman,, M. M. Thiaville,, L. K. Janka,, J. A. Jeung,, S. Nukoolkarn,, L. Govindasamy,, M. Agbandje-McKenna,, R. McKenna,, W. Leelamanit,, M. M. Goodenow, and, B. M. Dunn. 2006. Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir. Biochemistry 45:54685477.
26. Clemente, J. C.,, R. Hemrajani,, L. E. Blum,, M. M. Goodenow, and, B. M. Dunn. 2003. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N. Biochemistry 42:1502915035.
27. Coffin, J. M. 1995. HIV pathogenesis. Lines drawn in epitope wars. Nature 375:534535.
28. Condra, J. H.,, D. J. Holder,, W. A. Schleif,, O. M. Blahy,, R. M. Danovich,, L. J. Gabryelski,, D. J. Graham,, D. Laird,, J. C. Quintero,, A. Rhodes,, H. L. Robbins,, E. Roth,, M. Shivaprakash,, T. Yang,, J. A. Chodakewitz,, P. J. Deutsch,, R. Y. Leavitt,, F. E. Mas-sari,, J. W. Mellors,, K. E. Squires,, R. T. Steigbigel,, H. Teppler, and, E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:82708276.
29. Condra, J. H.,, C. J. Petropoulos,, R. Ziermann,, W. A. Schleif,, M. Shivaprakash, and, E. A. Emini. 2000. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J. Infect. Dis. 182:758765.
30. Craig, J. C.,, I. B. Duncan,, D. Hockley,, C. Grief,, N. A. Roberts, and, J. S. Mills. 1991. Antiviral properties of Ro 31–8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Anti-vir. Res. 16:295305.
31. Darke, P. L.,, R. F. Nutt,, S. F. Brady,, V. M. Garsky,, T. M. Ciccarone,, C. T. Leu,, P. K. Lumma,, R. M. Freidinger,, D. F. Veber, and, I. S. Sigal. 1988. HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem. Biophys. Res. Commun. 156:297303.
32. da Silveira, V. L.,, L. Drachler Mde,, J. C. Leite, and, C. A. Pinheiro. 2003. Characteristics of HIV antiretroviral regimen and treatment adherence. Braz. J. Infect. Dis. 7:194201.
33. Deeks, S. G.,, F. M. Hecht,, M. Swanson,, T. Elbeik,, R. Loftus,, P. T. Cohen, and, R. M. Grant. 1999. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 13:F35F43.
34. Dejesus, E.,, R. Ortiz,, H. Khanlou,, E. Voronin,, J. V. Luzen,, J. Andrade-Villanueva,, J. Fourie,, S. D. Meyer,, M. Haley,, E. Lefebvre,, C. V. Abeele, and, S. Spinosa-Guzman. 2007. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treatment-naïve HIV-1-infected patients at week 48: ARTEMIS. Inter-sci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
35. De Meyer, S.,, H. Azijn,, D. Surleraux,, D. Jochmans,, A. Tahri,, R. Pauwels,, P. Wigerinck, and, M. P. de Bethune. 2005. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49:23142321.
36. Dorsey, B. D.,, R. B. Levin,, S. L. McDaniel,, J. P. Vacca,, J. P. Guare,, P. L. Darke,, J. A. Zugay,, E. A. Emini,, W. A. Schleif,, J. C. Quintero, et al. 1994. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37:34433451.
37. Doyon, L.,, G. Croteau,, D. Thibeault,, F. Poulin,, L. Pilote, and, D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:37633769.
38. Doyon, L.,, S. Tremblay,, L. Bourgon,, E. Wardrop, and, M. G. Cordingley. 2005. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antivir. Res. 68:2735.
39. Dreyer, G. B.,, J. C. Boehm,, B. Chenera,, R. L. DesJarlais,, A. M. Hassell,, T. D. Meek,, T. A. Tomaszek, Jr., and, M. Lewis. 1993. A symmetric inhibitor binds HIV-1 protease asymmetrically. Biochemistry 32:937947.
40. Elbeik, T.,, B. S. Hoo,, M. E. Campodonico,, J. Dileanis,, F. F. Fay,, R. L. Bortolozzi,, M. S. Benetti,, O. H. Fay,, N. Marlowe,, O. Petrauskene,, D. Chernoff,, L. Smith, and, V. L. Ng. 2001. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy. J. Hum. Virol. 4:317328.
41. Ergun-Longmire, B.,, K. Lin-Su,, A. M. Dunn,, L. Chan,, K. Ham,, C. Sison,, J. Stavola, and, M. G. Vogiatzi. 2006. Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus. Endocr. Pract. 12:514521.
42. Erickson, J. W.,, S. V. Gulnik, and, M. Markowitz. 1999. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 13 (Suppl. A):S189S204.
43. Eron, J., Jr.,, P. Yeni,, J. Gathe, Jr.,, V. Estrada,, E. DeJesus,, S. Staszewski,, P. Lackey,, C. Katlama,, B. Young,, L. Yau,, D. Sutherland-Phillips,, P. Wannamaker,, C. Vavro,, L. Patel,, J. Yeo, and, M. Shaefer. 2006. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368:476482.
44. Falcoz, C.,, J. M. Jenkins,, C. Bye,, T. C. Hardman,, K. B. Kenney,, S. Studenberg,, H. Fuder, and, W. T. Prince. 2002. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J. Clin. Pharmacol. 42:887898.
45. Fellay, J.,, C. Marzolini,, E. R. Meaden,, D. J. Back,, T. Buclin,, J. P. Chave,, L. A. Decosterd,, H. Furrer,, M. Opravil,, G. Pantaleo,, D. Retelska,, L. Ruiz,, A. H. Schinkel,, P. Vernazza,, C. B. Eap, and, A. Telenti. 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:3036.
46. Flexner, C. 2000. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu. Rev. Pharmacol. Toxicol. 40:649674.
47. Ford, J.,, S. H. Khoo, and, D. J. Back. 2004. The intracellular pharmacology of antiretroviral protease inhibitors. J. Antimicrob. Chemother. 54:982990.
48. Friedland, G. H., and, A. Williams. 1999. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 13(Suppl. 1):S61S72.
49. Gatanaga, H.,, Y. Suzuki,, H. Tsang,, K. Yoshimura,, M. F. Kavlick,, K. Nagashima,, R. J. Gorelick,, S. Mardy,, C. Tang,, M. F. Summers, and, H. Mitsuya. 2002. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J. Biol. Chem. 277:59525961.
50. Gathe, J. C., Jr.,, R. Wood,, I. Sanne,, E. DeJesus,, S. Dirk,, A. Gladysz,, C. Garris,, N. Givens,, R. Elston, and, J. Yeo. 2006. Long-term (120-week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Clin. Ther. 28:745754.
51. Ghosn, J.,, I. Pellegrin,, C. Goujard,, C. Deveau,, J. P. Viard,, J. Galimand,, M. Harzic,, C. Tamalet,, L. Meyer,, C. Rouzioux, and, M. L. Chaix. 2006. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 20:159170.
52. Gong, Y. F.,, B. S. Robinson,, R. E. Rose,, C. Deminie,, T. P. Spicer,, D. Stock,, R. J. Colonno, and, P. F. Lin. 2000. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. 44:23192326.
53. Gottesman, M. M., and, I. Pastan. 1993. Biochemistry of multi-drug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:385427.
54. Gross, R.,, B. Yip,, E. Wood,, D. Bangsberg,, A. Justice,, J. Montaner, and, R. Hogg. 2006. Boosted PI are more forgiving of suboptimal adherence than non-boosted PI or NNRT. 13th Conf. Retrovir. Opportun. Infect., Denver, CO.
55. Gulick, R. M.,, J. W. Mellors,, D. Havlir,, J. J. Eron,, C. Gonzalez,, D. McMahon,, D. D. Richman,, F. T. Valentine,, L. Jonas,, A. Meibohm,, E. A. Emini, and, J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734739.
56. Hammer, S. M.,, K. E. Squires,, M. D. Hughes,, J. M. Grimes,, L. M. Demeter,, J. S. Currier,, J. J. Eron, Jr.,, J. E. Feinberg,, H. H. Balfour, Jr.,, L. R. Deyton,, J. A. Chodakewitz,, M. A. Fischl, et al. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725733.
57. Harrigan, P. R.,, R. S. Hogg,, W. W. Dong,, B. Yip,, B. Wynhoven,, J. Woodward,, C. J. Brumme,, Z. L. Brumme,, T. Mo,, C. S. Alexander, and, J. S. Montaner. 2005. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J. Infect. Dis. 191:339347.
58. Harzic, M.,, I. Pellegrin,, C. Deveau,, M. L. Chaix,, B. Dubeaux,, I. Garrigue,, N. Ngo,, C. Rouzioux,, C. Goujard,, B. Hoen,, D. Sereni,, J. F. Delfraissy, and, L. Meyer. 2002. Genotypic drug resistance during HIV-1 primary infection in France (1996–1999): frequency and response to treatment. AIDS 16:793796.
59. Hirsch, M. S.,, B. Conway,, R. T. D’Aquila,, V. A. Johnson,, F. BrunVezinet,, B. Clotet,, L. M. Demeter,, S. M. Hammer,, D. M. Jacobsen,, D. R. Kuritzkes,, C. Loveday,, J. W. Mellors,, S. Vella,, D. D. Richman, et al. 1998. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 279:19841991.
60. Hoetelmans, R. M. 1999. Pharmacology of antiretroviral drugs. Antivir. Ther. 4 (Suppl. 3):2941.
61. Holguin, A.,, E. Paxinos,, K. Hertogs,, C. Womac, and, V. Soriano. 2004. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J. Clin. Virol. 31:215220.
62. Hu, W. S., and, H. M. Temin. 1990. Retroviral recombination and reverse transcription. Science 250:12271233.
63. Hunt, P. W.,, S. G. Deeks,, B. Rodriguez,, H. Valdez,, S. B. Shade,, D. I. Abrams,, M. M. Kitahata,, M. Krone,, T. B. Neilands,, R. J. Brand,, M. M. Lederman, and, J. N. Martin. 2003. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 17:19071915.
64. Jacobsen, H.,, K. Yasargil,, D. L. Winslow,, J. C. Craig,, A. Krohn,, I. B. Duncan, and, J. Mous. 1995. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31–8959. Virology 206:527534.
65. Janneh, O.,, A. Owen,, B. Chandler,, R. C. Hartkoorn,, C. A. Hart,, P. G. Bray,, S. A. Ward,, D. J. Back, and, S. H. Khoo. 2005. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 19:20972102.
66. Johnson, V. A.,, F. Brun-Vezinet,, B. Clotet,, H. F. Gunthard,, D. R. Kuritzkes,, D. Pillay,, J. M. Schapiro, and, D. D. Richman. 2007. Update of the drug resistance mutations in HIV-1: 2007. Top. HIV Med. 15:119125.
67. Juliano, R. L., and, V. Ling. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455:152162.
68. Kaldor, S. W.,, V. J. Kalish,, J. F. Davies II,, B. V. Shetty,, J. E. Fritz,, K. Appelt,, J. A. Burgess,, K. M. Campanale,, N. Y. Chirgadze,, D. K. Clawson,, B. A. Dressman,, S. D. Hatch,, D. A. Khalil,, M. B. Kosa,, P. P. Lubbehusen,, M. A. Muesing,, A. K. Patick,, S. H. Reich,, K. S. Su, and, J. H. Tatlock. 1997. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40:39793985.
69. Kaufmann, D.,, G. Pantaleo,, P. Sudre, and, A. Telenti. 1998. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 351:723724.
70. Kempf, D. J.,, K. C. Marsh,, G. Kumar,, A. D. Rodrigues,, J. F. Denissen,, E. McDonald,, M. J. Kukulka,, A. Hsu,, G. R. Granneman,, P. A. Baroldi,, E. Sun,, D. Pizzuti,, J. J. Plattner,, D. W. Norbeck, and, J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654660.
71. King, J. R.,, H. Wynn,, R. Brundage, and, E. P. Acosta. 2004. Pharmacokinetic enhancement of protease inhibitor therapy. Clin. Pharmacokinet. 43:291310.
72. King, M. S.,, S. C. Brun, and, D. J. Kempf. 2005. Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J. Infect. Dis. 191:20462052.
73. Knobel, H.,, I. Escobar,, R. Polo,, L. Ortega,, M. T. Martin-Conde,, J. L. Casado,, C. Codina,, J. Fernandez,, M. J. Galindo,, O. Ibarra,, M. Llinas,, C. Miralles,, M. Riera,, C. R. Fumaz,, A. Segador,, F. Segura, and, L. Chamorro. 2005. Recommendations from GESIDA/ SEFH/PNS to improve adherence to antiviral treatment (2004). Enferm. Infecc. Microbiol. Clin. 23:221231. (In Spanish.)
74. Kotler, M.,, R. A. Katz,, W. Danho,, J. Leis, and, A. M. Skalka. 1988. Synthetic peptides as substrates and inhibitors of a retroviral protease. Proc. Natl. Acad. Sci. USA 85:41854189.
75. Krishna, R., and, L. D. Mayer. 2000. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11:265283.
76. Larder, B. A.,, K. Hertogs,, S. Bloor,, C. H. van den Eynde,, W. DeCian,, Y. Wang,, W. W. Freimuth, and, G. Tarpley. 2000. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 14:19431948.
77. Ledergerber, B.,, M. Egger,, M. Opravil,, A. Telenti,, B. Hirschel,, M. Battegay,, P. Vernazza,, P. Sudre,, M. Flepp,, H. Furrer,, P. Francioli, and, R. Weber. 1999. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 353:863868.
78. Lillehoj, E. P.,, F. H. Salazar,, R. J. Mervis,, M. G. Raum,, H. W. Chan,, N. Ahmad, and, S. Venkatesan. 1988. Purification and structural characterization of the putative Gag-Pol protease of human immunodeficiency virus. J. Virol. 62:30533058.
79. Little, S. J.,, S. Holte,, J. P. Routy,, E. S. Daar,, M. Markowitz,, A. C. Collier,, R. A. Koup,, J. W. Mellors,, E. Connick,, B. Conway,, M. Kilby,, L. Wang,, J. M. Whitcomb,, N. S. Hellmann, and, D. D. Richman. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385394.
80. Logsdon, B. C.,, J. F. Vickrey,, P. Martin,, G. Proteasa,, J. I. Koepke,, S. R. Terlecky,, Z. Wawrzak,, M. A. Winters,, T. C. Merigan, and, L. C. Kovari. 2004. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity. J. Virol. 78:31233132.
81. Lucas, G. M.,, R. E. Chaisson, and, R. D. Moore. 1999. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 131:8187.
82. Luque, I., and, E. Freire. 2002. Structural parameterization of the binding enthalpy of small ligands. Proteins 49:181190.
83. Luque, I., and, E. Freire. 1998. Structure-based prediction of binding affinities and molecular design of peptide ligands. Methods Enzymol. 295:100127.
84. MacArthur, R. D.,, R. M. Novak,, G. Peng,, L. Chen,, Y. Xiang,, K. H. Hullsiek,, M. J. Kozal,, M. van den Berg-Wolf,, C. Henely,, B. Schmetter, and, M. Dehlinger. 2006. A comparison of three highly active antiretroviral treatment strategies consisting of nonnucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 368:21252135.
85. Maggiolo, F.,, L. Ravasio,, D. Ripamonti,, G. Gregis,, G. Quinzan,, C. Arici,, M. Airoldi, and, F. Suter. 2005. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin. Infect. Dis. 40:158163.
86. Maguire, M. F.,, R. Guinea,, P. Griffin,, S. Macmanus,, R. C. Elston,, J. Wolfram,, N. Richards,, M. H. Hanlon,, D. J. Porter,, T. Wrin,, N. Parkin,, M. Tisdale,, E. Furfine,, C. Petropoulos,, B. W. Snowden, and, J. P. Kleim. 2002. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 76:73987406.
87. Malet, I.,, B. Roquebert,, C. Dalban,, M. Wirden,, B. Amellal,, R. Agher,, A. Simon,, C. Katlama,, D. Costagliola,, V. Calvez, and, A. G. Marcelin. 2007. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J. Infect. 54:367374.
88. Markowitz, M.,, H. Mohri,, S. Mehandru,, A. Shet,, L. Berry,, R. Kalyanaraman,, A. Kim,, C. Chung,, P. Jean-Pierre,, A. Horowitz,, M. La Mar,, T. Wrin,, N. Parkin,, M. Poles,, C. Petropoulos,, M. Mullen,, D. Boden, and, D. D. Ho. 2005. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 365:10311038.
89. Martin, P.,, J. F. Vickrey,, G. Proteasa,, Y. L. Jimenez,, Z. Wawrzak,, M. A. Winters,, T. C. Merigan, and, L. C. Kovari. 2005. “Wide-open” 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target. Structure 13:18871895.
90. Martinez, E., and, J. M. Gatell. 1999. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipo-dystrophy syndrome. Curr. Opin. Infect. Dis. 12:1319.
91. Martinez, J. L.,, R. McArthur,, J. Vickrey,, P. Martin,, G. Proteasa,, K. Kondapalli,, Y. Jimenez,, W. Wawrzak,, M. Winters,, T. Merigan, and, L. Kovari. 2004. The multi-drug resistance protease represents a novel drug target. 44th Annu. Intersci. Conf. Anti-microb. Agents Chemother. American Society for Microbiology, Washington, DC.
92. Martinez-Picado, J.,, A. V. Savara,, L. Sutton, and, R. T. D’Aquila. 1999. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73:37443752.
93. McCallister, S.,, H. Valdez,, K. Curry,, T. MacGregor,, M. Borin,, W. Freimuth,, Y. Wang, and, D. L. Mayers. 2004. A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 35:376382.
94. Miller, M.,, J. Schneider,, B. K. Sathyanarayana,, M. V. Toth,, G. R. Marshall,, L. Clawson,, L. Selk,, S. B. Kent, and, A. Wlodawer. 1989. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science 246:11491152.
95. Mocroft, A.,, L. Ruiz,, P. Reiss,, B. Ledergerber,, C. Katlama,, A. Lazzarin,, F. D. Goebel,, A. N. Phillips,, B. Clotet, and, J. D. Lundgren. 2003. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 17:17411751.
96. Molla, A.,, M. Korneyeva,, Q. Gao,, S. Vasavanonda,, P. J. Schipper,, H. M. Mo,, M. Markowitz,, T. Chernyavskiy,, P. Niu,, N. Lyons,, A. Hsu,, G. R. Granneman,, D. D. Ho,, C. A. Boucher,, J. M. Leonard,, D. W. Norbeck, and, D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760766.
97. Montes, M. L.,, F. Pulido,, C. Barros,, E. Condes,, R. Rubio,, C. Cepeda,, F. Dronda,, A. Antela,, J. Sanz,, E. Navas,, P. Miralles,, J. Berenguer,, S. Perez,, A. Zapata,, J. J. Gonzalez-Garcia,, J. M. Pena,, J. J. Vazquez, and, J. R. Arribas. 2005. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J. Antimicrob. Chemother. 55:800804.
98. Moyle, G. J., and, D. Back. 2001. Principles and practice of HIVprotease inhibitor pharmacoenhancement. HIV Med. 2:105113.
99. Myint, L.,, M. Matsuda,, Z. Matsuda,, Y. Yokomaku,, T. Chiba,, A. Okano,, K. Yamada, and, W. Sugiura. 2004. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:444452.
100. Nair, A. C.,, S. Miertus,, A. Tossi, and, D. Romeo. 1998. A computational study of the resistance of HIV-1 aspartic protease to the inhibitors ABT-538 and VX-478 and design of new analogues. Biochem. Biophys. Res. Commun. 242:545551.
101. Nijhuis, M.,, R. Schuurman,, D. de Jong,, J. Erickson,, E. Gust-china,, J. Albert,, P. Schipper,, S. Gulnik, and, C. A. Boucher. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:23492359.
102. Nijhuis, M.,, N. M. van Maarseveen,, S. Lastere,, P. Schipper,, E. Coakley,, B. Glass,, M. Rovenska,, D. de Jong,, C. Chappey,, I. W. Goedegebuure,, G. Heilek-Snyder,, D. Dulude,, N. Cammack,, L. Brakier-Gingras,, J. Konvalinka,, N. Parkin,, H. G. Krausslich,, F. Brun-Vezinet, and, C. A. Boucher. 2007. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med. 4:e36.
103. Noble, S., and, D. Faulds. 1996. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52:93112.
104. Ntemgwa, M.,, B. G. Brenner,, M. Oliveira,, D. Moisi, and, M. A. Wainberg. 2007. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob. Agents Chemother. 51:604610.
105. Ode, H.,, M. Ota,, S. Neya,, M. Hata,, W. Sugiura, and, T. Hoshino. 2005. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases. J. Phys. Chem. B 109:565574.
106. Ogden, R., and, C. Flexner. 2001. Protease Inhibitors in AIDS Therapy, 1st ed., vol. 1. Marcel Dekker AG, New York, NY.
107. Ohtaka, H.,, S. Muzammil,, A. Schon,, A. Velazquez-Campoy,, S. Vega, and, E. Freire. 2004. Thermodynamic rules for the design of high affinity HIV-1 protease inhibitors with adaptability to mutations and high selectivity towards unwanted targets. Int. J. Biochem. Cell. Biol. 36:17871799.
108. Ohtaka, H.,, A. Velazquez-Campoy,, D. Xie, and, E. Freire. 2002. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci. 11:19081916.
109. Park, S., and, P. J. Sinko. 2005. P-glycoprotein and multidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J. Pharmacol. Exp. Ther. 312:12491256.
110. Partaledis, J. A.,, K. Yamaguchi,, M. Tisdale,, E. E. Blair,, C. Falcione,, B. Maschera,, R. E. Myers,, S. Pazhanisamy,, O. Futer,, A. B. Cullinan, et al. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:52285235.
111. Paterson, D. L.,, S. Swindells,, J. Mohr,, M. Brester,, E. N. Vergis,, C. Squier,, M. M. Wagener, and, N. Singh. 2000. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133:2130.
112. Patick, A. K.,, H. Mo,, M. Markowitz,, K. Appelt,, B. Wu,, L. Mu-sick,, V. Kalish,, S. Kaldor,, S. Reich,, D. Ho, and, S. Webber. 1996. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Anti-microb. Agents Chemother. 40:292297.
113. Petersen, J. L., and, D. K. McGuire. 2005. Impaired glucose tolerance and impaired fasting glucose—a review of diagnosis, clinical implications and management. Diab. Vasc. Dis. Res. 2:915.
114. Piliero, P. J. 2002. Atazanavir: a novel HIV-1 protease inhibitor. Expert Opin. Investig. Drugs 11:12951301.
115. Preston, B. D.,, B. J. Poiesz, and, L. A. Loeb. 1988. Fidelity of HIV-1 reverse transcriptase. Science 242:11681171.
116. Quiñones-Mateu, M. E., and, E. J. Arts. 2001. HIV-1 fitness: implications for drug resistance, disease progression, and global epidemic evolution, p. 134–170. In C. Kuiken,, B. Foley,, B. Hahn,, P. Marx,, F. McCutchan,, J. W. Mellors,, S. Wolinsky, and, B. Korber (ed.), HIV Sequence Compendium 2001. Publ. no. 02-2877. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
117. Quinones-Mateu, M. E., and, E. J. Arts. 2002. Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist. Updates 5:224.
118. Rathbun, R. C., and, D. R. Rossi. 2002. Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann. Pharmacother. 36:702706.
119. Resch, W.,, R. Ziermann,, N. Parkin,, A. Gamarnik, and, R. Swanstrom. 2002. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. J. Virol. 76:86598666.
120. Riddler, S.,, R. Haubrich,, G. DiRienzo,, L. Peeples,, W. G. Powderly,, K. L. Klingman,, K. W. Garren,, T. George,, J. F. Rooney,, B. Brizz,, D. Havlir,, J. W. Mellors, and the, A. C. T., G. S. Team. 2006. A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection—ACTG 5142, abstr. THLB0204. Program and Abstracts of the XVIth International AIDS Conference, 13 to 18 August 2006, Toronto, Canada.
121. Robinson, B. S.,, K. A. Riccardi,, Y. F. Gong,, Q. Guo,, D. A. Stock,, W. S. Blair,, B. J. Terry,, C. A. Deminie,, F. Djang,, R. J. Colonno, and, P. F. Lin. 2000. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44:20932099.
122. Rodes, B.,, C. Toro,, J. A. Sheldon,, V. Jimenez,, K. Mansinho, and, V. Soriano. 2006. High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. AIDS 20:127129.
123. Rodriguez Novoa, S.,, P. Barreiro,, A. Rendon,, A. Barrios,, A. Corral,, I. Jimenez-Nacher,, J. Gonzalez-Lahoz, and, V. Soriano. 2006. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C#x2192;T polymorphism at the multidrug resistance gene 1. Clin. Infect. Dis. 42:291295.
124. Roge, B. T.,, T. S. Barfod,, O. Kirk,, T. L. Katzenstein,, N. Obel,, H. Nielsen,, C. Pedersen,, L. R. Mathiesen,, J. D. Lundgren, and, J. Gerstoft. 2004. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. HIV Med. 5:344351.
125. Rotger, M.,, P. Taffe,, G. Bleiber,, H. F. Gunthard,, H. Furrer,, P. Vernazza,, H. Drechsler,, E. Bernasconi,, M. Rickenbach, and, A. Telenti. 2005. Gilbert syndrome and the development of anti-retroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. 192:13811386.
126. Sanches, M.,, S. Krauchenco,, N. H. Martins,, A. Gustchina,, A. Wlodawer, and, I. Polikarpov. 2007. Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development. J. Mol. Biol. 369:10291040.
127. Schechter, I., and, A. Berger. 1967. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27:157162.
128. Sekar, V.,, S. Spinosa-Guzman,, E. Lefebvre, and, R. Hoetelmans. 2006. Clinical pharmacology of TMC114—a new HIV protease inhibitor. XVIth Int. AIDS Soc. Conf., Toronto, Canada. http:// www.natap.org/2006/IAS/IAS_76.htm.
129. Servais, J.,, C. Lambert,, E. Fontaine,, J.-M. Plesseria,, I. Robert,, V. Arendt,, T. Staub,, F. Schneider,, R. Hemmer,, G. Burtonboy, and, J.-C. Schmit. 2001. Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor. Antimicrob. Agents Chemother. 45:893900.
130. Sethi, A. K.,, D. D. Celentano,, S. J. Gange,, R. D. Moore, and, J. E. Gallant. 2003. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin. Infect. Dis. 37:11121118.
131. Sham, H. L.,, D. A. Betebenner,, X. Chen,, A. Saldivar,, S. Vasavanonda,, D. J. Kempf,, J. J. Plattner, and, D. W. Norbeck. 2002. Synthesis and structure-activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir). Bioorg. Med. Chem. Lett. 12:11851187.
132. Sham, H. L.,, D. J. Kempf,, A. Molla,, K. C. Marsh,, G. N. Kumar,, C. M. Chen,, W. Kati,, K. Stewart,, R. Lal,, A. Hsu,, D. Betebenner,, M. Korneyeva,, S. Vasavanonda,, E. McDonald,, A. Saldivar,, N. Wideburg,, X. Chen,, P. Niu,, C. Park,, V. Jayanti,, B. Grabowski,, G. R. Granneman,, E. Sun,, A. J. Japour,, J. M. Leonard,, J. J. Plattner, and, D. W. Norbeck. 1998. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Anti-microb. Agents Chemother. 42:32183224.
133. Sharom, F. J.,, X. Yu, and, C. A. Doige. 1993. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J. Biol. Chem. 268:2419724202.
134. Shuter, J.,, J. Sarlo,, T. Kanmaz,, R. Rode, and, B. Zingman. 2006. The “95% adherence rule” may not apply to lopinavir/ritonavir (LPV/r) based HAART regimens, abstr. TUPE0110. Program Abstr. XVI Int. AIDS Conf., 13 to 18 August 2006, Toronto, Canada.
135. Smit, T. K.,, B. J. Brew,, W. Tourtellotte,, S. Morgello,, B. B. Gelman, and, N. K. Saksena. 2004. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J. Virol. 78:1013310148.
136. Smith, K.,, W. Weinberg,, E. DeJesus,, M. Fischl,, Q. Liao,, L. Ross, and, T. Lancaster. 2006. Efficacy and safety of once daily boosted fosamprenavir or atazanavir with tenofovir/emtricitabine in antiretroviral-naive HIV-1 infected patients: 24 week results from COL103952 (ALERT), abstr. H1670a. Programs Abstr. 46th Annu. Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
137. Squires, K.,, A. Lazzarin,, J. M. Gatell,, W. G. Powderly,, V. Pokrovskiy,, J. F. Delfraissy,, J. Jemsek,, A. Rivero,, W. Rozenbaum,, S. Schrader,, M. Sension,, A. Vibhagool,, A. Thiry, and, M. Giordano. 2004. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. 36:10111019.
138. Sudano, I.,, L. E. Spieker,, G. Noll,, R. Corti,, R. Weber, and, T. F. Luscher. 2006. Cardiovascular disease in HIV infection. Am. Heart J. 151:11471155.
139. Surleraux, D. L.,, A. Tahri,, W. G. Verschueren,, G. M. Pille,, H. A. de Kock,, T. H. Jonckers,, A. Peeters,, S. De Meyer,, H. Azijn,, R. Pauwels,, M. P. de Bethune,, N. M. King,, M. Prabu-Jeyabalan,, C. A. Schiffer, and, P. B. Wigerinck. 2005. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J. Med. Chem. 48:18131822.
140. Tang, J. H.,, J. S. Sheffield,, J. Grimes,, B. McElwee,, S. W. Roberts,, V. Laibl,, D. D. McIntire, and, G. D. Wendel, Jr. 2006. Effect of protease inhibitor therapy on glucose intolerance in pregnancy. Obstet. Gynecol. 107:11151119.
141. Thaisrivongs, S., and, J. W. Strohbach. 1999. Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Bio-polymers 51:5158.
142. Thomas, S. A. 2004. Anti-HIV drug distribution to the central nervous system. Curr. Pharm. Des. 10:13131324.
143. Tie, Y.,, P. I. Boross,, Y. F. Wang,, L. Gaddis,, F. Liu,, X. Chen,, J. Tozser,, R. W. Harrison, and, I. T. Weber. 2005. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J. 272:52655277.
144. Torti, C.,, E. Quiros-Roldan,, L. Monno,, A. Patroni,, A. Saracino,, G. Angarano,, C. Tinelli,, S. Lo Caputo,, V. Tirelli,, F. Mazzotta, and, G. Carosi. 2004. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. J. Med. Virol. 74:2933.
145. Toth, G., and, A. Borics. 2006. Closing of the flaps of HIV-1 protease induced by substrate binding: a model of a flap closing mechanism in retroviral aspartic proteases. Biochemistry 45:66066614.
146. Toth, G., and, A. Borics. 2006. Flap opening mechanism of HIV-1 protease. J. Mol. Graph. Model. 24:465474.
147. Tozzini, V.,, J. Trylska,, C. E. Chang, and, J. A. McCammon. 2007. Flap opening dynamics in HIV-1 protease explored with a coarse-grained model. J. Struct. Biol. 157:606615.
148. Vacca, J. P.,, B. D. Dorsey,, W. A. Schleif,, R. B. Levin,, S. L. McDaniel,, P. L. Darke,, J. Zugay,, J. C. Quintero,, O. M. Blahy,, E. Roth, et al. 1994. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:40964100.
149. Vandamme, A. M.,, A. Sonnerborg,, M. Ait-Khaled,, J. Albert,, B. Asjo,, L. Bacheler,, D. Banhegyi,, C. Boucher,, F. Brun-Vezinet,, R. Camacho,, P. Clevenbergh,, N. Clumeck,, N. Dedes,, A. De Luca,, H. W. Doerr,, J. L. Faudon,, G. Gatti,, J. Gerstoft,, W. W. Hall,, A. Hatzakis,, N. Hellmann,, A. Horban,, J. D. Lundgren,, D. Kempf,, M. Miller,, V. Miller,, T. W. Myers,, C. Nielsen,, M. Opravil,, L. Palmisano,, C. F. Perno,, A. Phillips,, D. Pillay,, T. Pumarola,, L. Ruiz,, M. Salminen,, J. Schapiro,, B. Schmidt,, J. C. Schmit,, R. Schuurman,, E. Shulse,, V. Soriano,, S. Staszewski,, S. Vella,, M. Youle,, R. Ziermann, and, L. Perrin. 2004. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir. Ther. 9:829848.
150. Velazquez-Campoy, A.,, S. Muzammil,, H. Ohtaka,, A. Schon,, S. Vega, and, E. Freire. 2003. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design. Curr. Drug Targets Infect. Disord. 3:311328.
151. Velazquez-Campoy, A.,, S. Vega, and, E. Freire. 2002. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry 41:86138619.
152. Verheyen, J.,, E. Litau,, T. Sing,, M. Daumer,, M. Balduin,, M. Oette,, G. Fatkenheuer,, J. K. Rockstroh,, U. Schuldenzucker,, D. Hoffmann,, H. Pfister, and, R. Kaiser. 2006. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir. Ther. 11:879887.
153. von Moltke, L. L.,, D. J. Greenblatt,, S. X. Duan,, J. P. Daily,, J. S. Harmatz, and, R. I. Shader. 1998. Inhibition of desipramine hydroxylation (cytochrome P450–2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J. Pharm. Sci. 87:11841189.
154. Walmsley, S.,, B. Bernstein,, M. King,, J. Arribas,, G. Beall,, P. Ruane,, M. Johnson,, D. Johnson,, R. Lalonde,, A. Japour,, S. Brun, and, E. Sun. 2002. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 346:20392046.
155. Weiser, S. D.,, D. Guzman,, E. D. Riley,, R. Clark, and, D. R. Bangsberg. 2004. Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clin. Trials 5:278287.
156. Winston, A.,, G. Hales,, J. Amin,, E. van Schaick,, D. A. Cooper, and, S. Emery. 2005. The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. AIDS 19:13931399.
157. Winzer, R.,, P. Langmann,, M. Zilly,, F. Tollmann,, J. Schubert,, H. Klinker, and, B. Weissbrich. 2003. No influence of the Pglycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur. J. Med. Res. 8:531534.
158. Witvrouw, M.,, C. Pannecouque,, W. M. Switzer,, T. M. Folks,, E. De Clercq, and, W. Heneine. 2004. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. 9:5765.
159. Yasuda, J. M.,, C. Miller,, J. S. Currier,, D. N. Forthal,, C. A. Kemper,, G. N. Beall,, J. G. Tilles,, E. V. Capparelli,, J. A. McCutchan, and, R. H. Haubrich. 2004. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. Antivir. Ther. 9:753761.
160. Yu, K., and, E. S. Daar. 2000. Dual protease inhibitor therapy in the management of the HIV-1. Expert Opin. Pharmacother. 1:13311342.
161. Zhang, Y. M.,, H. Imamichi,, T. Imamichi,, H. C. Lane,, J. Falloon,, M. B. Vasudevachari, and, N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:66626670.
162. Zolopa, A.,, W. Towner,, C. Zurawski,, G. Crofoot,, D. Butcher,, S. Wang,, J. Maa, and, D. Seekins. 2006. Resistance profile after treatment with an atazanavir-containing regimen: first interim analysis results from the IMPACT Study (BMS AI424–128), abstr. THPE0099. XVIth Int. AIDS Conf., 13 to 18 August 2006, Toronto, Canada.

Tables

Generic image for table
Table 1.

Drug resistance selection experiments with different HIV-1 PIs

Citation: Martinez-Cajas J, Wainberg M. 2009. Inhibitors of the Human Immunodeficiency Virus Protease, p 113-135. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch7
Generic image for table
Table 2.

Pharmacokinetic features of HIV PIs

Citation: Martinez-Cajas J, Wainberg M. 2009. Inhibitors of the Human Immunodeficiency Virus Protease, p 113-135. In LaFemina, Ph. D. R (ed), Antiviral Research. ASM Press, Washington, DC. doi: 10.1128/9781555815493.ch7

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error